Tobi and Amoxicillin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tobi (tobramycin) and Amoxicillin (amoxicillin). Common drug interactions include hospitalisation among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Tobi and Amoxicillin. It is created by eHealthMe based on reports of 55 people who take the same drugs from the FDA, and is updated regularly.

What is Tobi?

Tobi has active ingredients of tobramycin. eHealthMe is studying from 10,011 Tobi users. Check the latest studies of Tobi.

What is Amoxicillin?

Amoxicillin has active ingredients of amoxicillin. It is often used in infection. eHealthMe is studying from 99,235 Amoxicillin users. Check the latest studies of Amoxicillin.

On Jul, 13, 2026

55 people who take Tobi and Amoxicillin together, and have interactions are studied.

What are the common drug interactions of Tobi and Amoxicillin, by gender? *:

female:

Hospitalisation
Dyspnoea (difficult or laboured respiration)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Asthenia (weakness)
Dizziness
Fatigue (feeling of tiredness)
Deafness unilateral
Death
Diarrhoea
Drug hypersensitivity

male:

Pneumonia
Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
Pulmonary function test decreased
Staphylococcal infection (an infection with staphylococcus bacteria)
Central nervous system stimulation
Chills (felling of cold)
Constipation
Cystic fibrosis (disease of the secretary glands)
Dysphonia (speech disorder attributable to a disorder of phonation)
Fatigue (feeling of tiredness)

What are the common drug interactions of Tobi and Amoxicillin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Constipation
General physical health deterioration (weak health status)

10-19:

Hospitalisation
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Lung disorder (lung disease)
Pulmonary function test decreased
Central nervous system stimulation
Decreased appetite
Gallbladder disorder
Influenza
Weight decreased
Weight increased

20-29:

Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Pulmonary function test decreased
Staphylococcal infection (an infection with staphylococcus bacteria)
Weight decreased
Chills (felling of cold)
Fatigue (feeling of tiredness)
Headache (pain in head)
Infusion related reaction
Pain

30-39:

Asthenia (weakness)
Diarrhoea
Dizziness
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Flatulence (flatus expelled through the anus)
Hospitalisation
Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
Nausea (feeling of having an urge to vomit)
Respiration (transport of oxygen from the outside air to the cells within tissues)

40-49:

Back pain
Oxygen saturation decreased
Rash erythematous (redness of the skin)
Dyspnoea (difficult or laboured respiration)
Lung transplant rejection (failure of lung transplant)
Pneumonia
Red blood cell abnormality (abnormal red blood cells)
Weight increased

50-59:

Death
Blood creatine phosphokinase increased
Cerumen impaction
Colonic polyp (extra part of colon tissue grow in intestine)
Depression
Diverticulum (out pouching of a hollow (or a fluid-filled) structure in the body)
Ear infection
Eye disorder
Fatigue (feeling of tiredness)
Femur fracture

60+:

Deafness unilateral
Heart rate increased
Tinnitus (a ringing in the ears)
Asthenia (weakness)
Cystitis (inflammation of the wall of the bladder)
Dizziness
Drug hypersensitivity
Dysphonia (speech disorder attributable to a disorder of phonation)
Movement disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness)
Pneumonia

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 32 people, 58.18%
Bronchiectasis (abnormal widening of the bronchi or their branches, causing a risk of infection): 6 people, 10.91%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 4 people, 7.27%

* Approximation only. Some reports may have incomplete information.

Do you take Tobi and Amoxicillin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously